No Data
No Data
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
News Highlights: Top Company News of the Day - Friday at 7 PM ET
Novo Nordisk Stock Crashes on Obesity Drug Data. It's a Win for Eli Lilly. -- Barrons.com
FDA Approves First Medication for Obstructive Sleep Apnea
Eli Lilly Says FDA Approves Zepbound for Obstructive Sleep Apnea in Adults With Obesity
Unlock the Full List